PDE5 selective competitive inhibitors, sildenafil and tadalafil, have shown excellent outcomes in the treatment of systemic sclerosis (SSc)-related digital ulcers and pulmonary arterial hypertension (PAH) (Galiè et al., 2005; Ramani and Park, 2010). Here, PDE5A is linked to pulmonary arterial hypertension.